Genflow Biosciences Plc develops gene therapies for age-related diseases, with company news centered on its SIRT6-based longevity platform and related therapeutic programs. Updates include progress in canine gene therapy work, intellectual property publications for SIRT6 applications, technology collaborations supporting delivery and genomic analysis, and engagement with animal health and biotechnology partners.
Genflow's announcements also cover operating and financial results, warrant exercises and equity issuance, total voting rights, and shareholder approvals for capital authorities. The company trades in London under GENF and on OTCQB under GENFF, and its public updates frequently use UK regulatory news channels for market disclosures.
Genflow Biosciences (GENFF) received Japanese patent allowance for its SIRT6 gene therapy platform and signed additional animal health confidentiality agreements. The Japan Patent Office allowed all 16 claims covering SIRT6 variants for preventing or treating age-related diseases. The application is exclusively licensed to Genflow; registration remains subject to payment of the registration fee.
Additional animal health companies are evaluating the therapy for companion animals. An approximately EUR 0.76 million regional research grant application for an 18-month MASH research project was not approved at initial review. Genflow requested reopening of the file. The programme continues as planned, and financial guidance is unchanged because it did not assume the grant.
Genflow Biosciences (GENFF) is presenting interim results from its controlled SIRT6c gene-therapy study in aged dogs at the Animal Longevity Summit. The blinded trial enrolled 24 Beagles across four arms. At Day 182, mean epigenetic age, measured by a DNA-based ageing clock, fell 1.08 years with low-dose plasmid DNA, 0.48 years with high-dose plasmid DNA, 0.30 years with AAV8 delivery and 0.07 years with saline. No difference versus control reached statistical significance; results are directional and hypothesis-generating.
No treatment-related serious adverse events were observed. Preliminary muscle biopsies suggested preserved structure and regeneration in treated dogs. Intravenous plasmid DNA was selected as the veterinary programme's lead delivery method. The study was extended, with the pre-specified primary clock endpoint scheduled for Day 320. Genflow intends an asset sale or risk-sharing out-licence; discussions are underway.
Genflow Biosciences (GENFF) received notices to exercise warrants for 28,124,999 new ordinary shares, with the subscription funds already received.
The exercises brought in £309,375 in gross proceeds at an adjusted exercise price of 1.1p. The warrant terms provide for a price reset if Genflow completes a lower-priced share issuance or grants rights to subscribe for equity at a lower price during the exercise period. Genflow has applied for admission of the new shares to the FCA official list and LSE main market, expected on or around 8:00 a.m. on 2 October 2026. Following admission, issued shares and voting rights will total 594,534,781.
Genflow Biosciences (GENFF) reported its first-half 2026 results, including a £420,233 loss and completion of its canine SLAB trial. The loss narrowed from £737,618 a year earlier, while basic and diluted loss per share fell to 0.080 pence from 0.192 pence. Cash was £632,553 at 30 June 2026, up from £111,792 at year-end, after £1,148,875 in net proceeds from share issuance. Operations used £633,943 in cash during the half-year.
Genflow said the SLAB trial of GF-1004 in aged Beagles confirmed safety and tolerability; it plans to present full results on 2 October 2026. In its human programs, the company moved to mRNA-lipid nanoparticle delivery and initiated a glaucoma program with Iris Pharma and Acuitas. Administrative expenses fell to £454,311 from £982,725 a year earlier. Genflow remains debt-free and is seeking an extension of the Wallonia Region grant supporting GF-1002.
Genflow Biosciences (GENFF) reports that its SLAB clinical trial in aged beagle dogs met its primary endpoint of reducing biological age, as measured by the GRIM methylation clock. The randomized, blinded study enrolled 24 dogs over 10 years old into four groups: two naked DNA SIRT6 centenarian gene therapy dosing cohorts, a single-dose AAV8 group and a saline control group.
Treated animals showed a clear improvement signal versus controls on the biological age metric. Genflow also observed benefits across multiple functional and observable secondary measures, with full mechanistic and efficacy data to be presented at the Animal Longevity Summit in Toronto on 1–2 October 2026.
The company states that these results build on earlier positive interim muscle data and three-month safety and efficacy follow-up from 2026, and believes that achieving the primary endpoint strengthens the commercial attractiveness of its veterinary longevity programme for potential animal health partners.
Genflow Biosciences (GENFF) has appointed ON365 Partners as its investor relations adviser, effective immediately, replacing Harbor Access.
ON365 is a specialist investor relations and strategic advisory firm focused on healthcare and life sciences, providing capital markets counsel, investor engagement and corporate communications support to publicly listed companies. Genflow believes ON365’s sector focus and North American investor network will help support its centenarian SIRT6 gene therapy platform and expand dialogue with institutional and retail investors across its listings. The company thanks Harbor Access for its prior contribution to its investor relations programme.
Genflow Biosciences (OTCQB:GENFF, LSE:GENF) reported progress across its two main SIRT6 patent families covering its centenarian-derived SIRT6 variant (SIRT6c; N308K/A313S). The USPTO has published US patent application US 2026/0199524 A1 for using SIRT6c in preventing and/or treating NAFLD and NASH, naming Dr. Manlio Vinciguerra and Dr. Eric Leire as inventors and assigning rights to Genflow.
The USPTO also granted Track One prioritized examination for a foundational in-licensed US SIRT6 application for age-related diseases, from a family jointly owned by three academic institutions and exclusively licensed to Genflow. A corresponding European application is at the last stage before the EPO, and examination has been requested in Canada.
Genflow Biosciences (LSE:GENF, OTCQB:GENFF) issued a mid-year update for the six months to 30 June 2026, highlighting clinical, partnership, IP and corporate progress for its SIRT6 longevity platform.
The SLAB dog trial reported positive preliminary interim results in February, with all treatment groups showing superior survival versus controls during dosing, no adverse events and a favourable safety and tolerability profile. Three‑month follow-up in April indicated maintained improvements and no adverse events, suggesting early durability; full methylation clock and muscle histology data are due after trial completion at end‑July 2026. The blinded GF‑1004 Dog Aging Study continues, with a six‑month efficacy assessment expected in July 2026.
Genflow entered a fully funded, non‑dilutive LNP collaboration with Acuitas Therapeutics, expanded confidentiality agreements with Tier‑1 animal health companies, and saw publication of an international PCT patent on SIRT6 variants for muscular diseases. The company also advanced glaucoma and broader sarcopenia programmes and appointed Gad Berdugo as Independent Non‑Executive Chairman.
Genflow Biosciences (OTCQB:GENFF) reported that all 13 resolutions at its 29 June 2026 AGM were passed. Ordinary business included receiving 2025 accounts, approving the remuneration report, reappointing PKF Littlejohn as auditor and re-electing all directors.
Shareholders also approved a new share option scheme, authorising directors to allot shares for scheme options up to 14.34% and to allot further shares up to 33%. Special resolutions to disapply statutory pre-emption rights related to these allotment authorities were passed with over 98.7% support.
Genflow Biosciences (OTCQB:GENFF) announced that Independent Non-Executive Chairman Gad Berdugo will attend the BIO International Convention 2026 in San Diego from June 22-25.
He will speak on an RNA therapeutics panel focused on technical advances and clinical validation over the next 3-5 years.